Previous 10 | Next 10 |
In a note, Evercore ISI's Joshua Schimmer says Moderna's (NASDAQ: MRNA ) COVID-19 vaccine, mRNA-1273, is unlikely to be the best of the bunch but may wind up being "good enough" to get the first regulatory nod, adding that other candidates appear poised to offer higher immunogenicity, fewer ...
Many experts think that until an effective vaccine for the SARS-CoV-2 coronavirus is developed and widely deployed, the U.S. economy won't be able to truly return to normalcy. They're probably right. While air travel passenger volume has very gradually started to make a comeback from the extrem...
NEW ORLEANS, May 20, 2020 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Moderna, Inc. (NasdaqGS: MRNA). Such investors are...
Stocks continue their unlikely recovery in the face of skepticism among participants who see more trouble ahead for the global economy. The thinking of many analysts and observers is that the 34% rebound in the S&P 500 Index (SPX) has been nothing more than a massive bear market rally that...
Money Minting - Theory and Practice Usually, when investors refer to MMT, they mean Modern Monetary Theory , a macroeconomic framework that basically says monetarily sovereign countries like the U.S. do not need taxes or borrowing for spending since they can print as much as they need and...
Moderna Inc. Moderna (MDNRA), is, despite it's being everyone's latest pharma stock, going to have the same problems with their vaccine as Gilead with their drug for coronavirus. That's my opinion at least and it's informed by my knowledge of the political system. Nothing to do with the acc...
A Vaccine From A Different Time It is widely believed that Dr. Jonas Salk essentially gave away the Polio vaccine he discovered due to his moral stance of not profiteering off the suffering of children with the disability. Unfortunately, this popular myth is far from the whole truth . In ...
May 18th brought news from Moderna (MRNA) of the very first human results from trials of their closely-watched mRNA vaccine candidate (mRNA-1273) against the coronavirus. Here's Stat on the news, and here's Endpts - the results can be summed up pretty quickly, because it's all just at th...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Last issued in 1986, the Treasury is bringing back the 20-year bond, which will debut in a $20B auction later this afternoon. "Tha...
The Renaissance IPO Index rose 2.8% on Monday, and surpassed its all-time high in mid-day trading. The IPO Index is now up 12.9% for the year , outperforming the S&P 500 by 20 points, and the Nasdaq Composite by 10 points. The Renaissance IPO ETF (IPO) tracks the index, which is compo...
News, Short Squeeze, Breakout and More Instantly...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
2024-04-26 04:50:00 ET Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the vaccine declined, Moderna stock followed. Investors are worried...
GSK Plc (NYSE:GSK) has reportedly taken legal action against Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in a...